Page 213 - 2022_01-Haematologica-web

Phenogenomic features of post-transplant PBL
haematologica | 2022; 107(1)
205
Table 2. Morphologic and immunophenotypic features of post-transplant plasmablastic lymphomas.
Patient 1 2 3 4 5 6 7 8 9 10 11
Diagnosis PBL PBL PBL PBL M-PTLD PBL PBL PBL P-PTLD PBL PBL M-PTLD PBL PBL
IG heavy chain BCL2 IHC CMYC IHC P53 IHC
EMA+ EMA-/+
sIg-* IgM IgG IgA IgA ND >90% >90% <10% 20%
EMA+ EMA+
- IgG IgG IgG IgG
EMA-/+ EMA+
IgG - - IgA -
CD30 Ki-67 PD1/PDL1
--<5%<5%-10%70% 70% 60% >90% ND 90% 90% 50% 80% 60% 90% 50% >90% ND ND Mild/- Mild/- Rare/- Mild/- Mild/- Mild/10% Mild/- Rare/- ND
- - - - 10%
50% <10% 60% <10% <10% ND <10% 80% 20% 50% 30% 80% 30% 90% ND ND 10% 30% <10% <10% <10% 50% 30% 90% 40%
IgM ND IgG
70% >90% 20%
20% 20% 40%
30% <10% 10%
10% 20% 10%
70% 80% 90% 70%
50% 80%
(Plasma- cytoma)
(DLBCL)
MaturePC(%) <5 <5 <5 20 5
Necrosis No No No No No No Yes Yes No Yes No Yes Yes Yes Yes No Yes Yes Immunophenotype CD19-, CD19+, CD19-, CD19-, CD19-, CD19+, CD19-, CD19+, CD19+, CD20-, CD19+, CD19+, CD19+, CD19-, CD19+, CD19+, CD19-, CD19+,
CD20-, CD20-, CD20-, CD20-, CD20-, CD20+, CD20-, CD20-/+, CD20-/+, PAX5+, CD20-/+ PAX5-, PAX5+/-, PAX5-, PAX5-, PAX5-, PAX5+, PAX5+, PAX5+, PAX5+, CD79a+, PAX5+/-, CD79a-, CD79a+, CD79a-, CD79a-, CD79a-, CD79a+, CD79a-, CD79a-/+, CD79a+, CD138-, CD79a+,
5 5 <5 <5 10 10 20
20 20 <5
CD20+/-, CD20-, CD20-, CD20+, CD20-, CD20-, CD20-/+, AX5+/-, PAX5+/-, PAX5-, PAX5+, PAX5-, PAX5-, PAX5-/+, PCD79a+, CD79a+, CD79a-/+, CD79a+, CD79a+, CD79a+, CD79a+, CD138+, CD138-/+, CD138+, CD138+, CD138+, CD138+, CD138+/-, CD138-, CD138+, BCL6-, CD138-, CD138+, CD138+/-, CD138-, CD138-, D138+, CD138+, CD138+, MUM1+ BCL6-, BCL6-, BCL6-, BCL6-, BCL6-, BCL6-, BCL6-, BCL6-, CD10-, BCL6-, BCL6-, BCL6-, CD10+, BCL6+, BCL6-, BCL6-, BCL6+/-,
CD10+, CD10+, CD10-, CD10+, CD10-, CD10-, CD10-, CD10-, MUM1+, CD10-, CD10-, CD10-, BCL6-, CD10-, CD10-, CD10+, CD10+,
MUM1+, MUM1+, MUM1+, MUM1+, MUM1+, MUM1+, MUM1+, MUM1+, CD56- CD56+ CD56-, CD56+, CD56+, CD56- CD56-, CD56- CD56-,
MUM1+, MUM1+, MUM1+, MUM1+, MUM1-/+, MUM1+, MUM1+, MUM1+, CD56- CD56- CD56- CD56-, CD56-, CD56- CD56-, CD56-
with with macro- macro- phages+ phages+
Mild/30% Mild/20% Mild/20% Mild/- with with with
Moderate/ ND with macro-
Mild/- Mild/- with with macro- macro- phages+ phages+
EBER -++++++----++----+ Latencytype ND II 0/I II II II II NA NA NA NA III III NA NA NA NA II
MMRIHC ND ND ND ND ND ND ND MLH1-, PMS2-,
ND MLH1-, ND ND ND ND ND ND ND PMS2-,
MSH2+, MSH6+
MSH2+, MSH6-
PBL: plasmablastic lymphoma; M-PTLD: monomorphic post-transplant lymphoproliferative disorder; P-PTLD: polymorphic post-transplant lymphoproliferative disorder; DLBCL: diffuse large B-cell lymphoma; PC: plasma cells; IG: immunoglobulin; IHC: immunohistochemistry; ND: not determined; NA: not applicable; EBER: Epstein-Barr virus encoded small RNA; MMR: mismatch repair. *sIg negative by flow cytometry.
macro- macro- macro- phages+ phages+ phages+
phages+
30% 10% >90% 30% 40% <10% 30% <10% <10%
70% 30% <10% <10%
80% 20%
60% 90%